OncoMatch/Clinical Trials/NCT06540729
RC48 in Combination With AK104 and Bevacizumab in OCCC
Is NCT06540729 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer for ovary cancer.
Treatment: Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer — Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Biomarker criteria
Required: HER2 (ERBB2) IHC ≥1+ (IHC ≥1+)
HER2 IHC ≥1+.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immunotherapy (PD-1, PD-L1, CAR-T, CTLA-4)
Patients with a history of immunotherapy, including treatments targeting PD-1, PD-L1, CAR-T, and CTLA-4.
Lab requirements
Blood counts
white blood cell count ≥3.0×10^9/L, neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥80 g/L
Kidney function
creatinine ≤1.5× ULN
Liver function
AST ≤2.5× ULN, ALT ≤2.5× ULN, serum total bilirubin ≤1.5× ULN
Adequate bone marrow reserve function necessitates pre-operative blood routine parameters meeting specific criteria: white blood cell count ≥3.0×10^9/L, neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, and hemoglobin ≥80 g/L. Satisfactory organ function entails biochemical test results within defined limits: AST ≤2.5× upper limit of normal (ULN), ALT ≤2.5× ULN, serum total bilirubin ≤1.5× ULN, and creatinine ≤1.5× ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06540729 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 IHC ≥1+ is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify